SM
TGTX icon

SG3 Management’s TG Therapeutics TGTX Stock Holding History

SG3 Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,000
Closed -$1.93M – 1459
2020
Q4 		$1.93M Sell
37,000
-10,000
-21% -$338K 0.04% 393
2020
Q3 		$1.26M Buy
47,000
+37,000
+370% +$851K 0.05% 375
2020
Q2 		$195K Buy
+10,000
New +$161K 0.01% 485

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SG3 Management's TGTX Position: Q4 2021 in Review

SG3 Management sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 5,371 shares — an estimated $139K sold.

SG3 Management first reported a position in TGTX in Q2 2019 and held it in 5 quarters. The position peaked at $369K in Q2 2021. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

  • SG3 Management reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 5,371 TG Therapeutics shares in Q4 2021, an estimated $139K.
  • SG3 Management first reported a position in TG Therapeutics in Q2 2019 and held it in 5 quarters.
  • SG3 Management's TG Therapeutics position peaked at $369K in Q2 2021.
  • 194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.